低级别蛋白尿与IgA肾病不良肾脏结局的关联:系统综述与荟萃分析
该系统综述与荟萃分析纳入23项研究共15,289例IgA肾病患者,评估低级别蛋白尿(0.5-1.0 g/d)对肾脏结局的预后影响。结果显示,基线低级别蛋白尿较蛋白尿<0.5 g/d者不良肾脏结局风险显著增加(HR 1.73),时间平均低级别蛋白尿风险更高(HR 2.87)且eGFR年下降更快(-1.02 ml/min/1.73m²)。结论支持将长期蛋白尿控制<0.5 g/d作为治疗目标。
要点
- 低级别蛋白尿(0.5-1.0 g/d)显著增加IgA肾病不良肾脏结局风险。
- 时间平均低级别蛋白尿者eGFR年下降加快1.02 ml/min/1.73m²。
- 支持将长期蛋白尿控制<0.5 g/d作为IgA肾病治疗目标。
核心结论
- 低级别蛋白尿无论基线或时间平均评估,均是IgA肾病进展的重要预测因素。
- 结果支持近期临床指南推荐蛋白尿控制<0.5 g/d。
研究设计与样本
- 系统综述与荟萃分析,纳入23项研究共15,289例IgA肾病患者,其中15项贡献至少一项荟萃分析。
- 检索PubMed和Web of Science,采用随机效应模型合并数据,方案注册于Open Science Framework。
主要发现
- 基线低级别蛋白尿较蛋白尿<0.5 g/d者不良肾脏结局风险增加(合并HR 1.73,95%CI 1.36-2.20,9项研究)。
- 时间平均低级别蛋白尿与更高肾脏结局风险相关(合并HR 2.87,95%CI 1.48-5.56,7项研究)。
- 时间平均低级别蛋白尿者eGFR年下降更陡(均差-1.02 ml/min/1.73m²/年,95%CI -1.60至-0.45,4项研究)。
- 亚组分析和留一法敏感性分析与总体结果一致。
关键数值与推荐
- 低级别蛋白尿定义为0.5-1.0 g/d。
- 基线低级别蛋白尿合并HR 1.73(95%CI 1.36-2.20)。
- 时间平均低级别蛋白尿合并HR 2.87(95%CI 1.48-5.56)。
- eGFR年下降均差-1.02 ml/min/1.73m²/年(95%CI -1.60至-0.45)。
临床怎么用
- 应将长期蛋白尿控制<0.5 g/d作为IgA肾病关键治疗目标。
- 对低级别蛋白尿(0.5-1.0 g/d)患者应积极干预以降低肾脏进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Systematic review/meta-analysis of 23 studies (15,289 patients) quantified prognostic effect of low-grade proteinuria in IgA nephropathy. Low-grade proteinuria (0.5-1.0 g/d) linked to higher kidney risk (hazard ratio, 1.73-2.87) and faster eGFR decline (-1.02 ml/min per year). Long-term suppression below 0.5 g/d should be a key therapeutic goal, supporting current IgA nephropathy clinical guidelines. BACKGROUND: Overt proteinuria (>1.0 g/d) is a well-established risk factor for kidney disease progression in IgA nephropathy. However, recent evidence suggests that even low-grade proteinuria, typically defined as 0.5-1.0 g/d, may be clinically significant. The prognostic effect of low-grade proteinuria has not been systematically evaluated. METHODS: We conducted a systematic review and meta-analysis to evaluate the association between low-grade proteinuria and adverse kidney outcomes in patients with IgA nephropathy. A systematic literature search was performed on PubMed and Web of Science. Eligible studies included those reporting on kidney outcomes such as eGFR decline, kidney failure, or eGFR slope in relation to low-grade proteinuria measured either at baseline or during follow-up ( e.g ., time-averaged proteinuria). Data were synthesized using random-effects meta-analysis. The protocol was registered in the Open Science Framework REGISTRIES ( https://osf.io/5dfqr ). RESULTS: A total of 23 studies ( N =15,289) met the inclusion criteria, of which 15 contributed to at least one meta-analysis. Baseline low-grade proteinuria was significantly associated with an increased risk of adverse kidney outcomes compared with proteinuria below 0.5 g/d (pooled hazard ratio, 1.73; 95% confidence interval [CI], 1.36 to 2.20; nine studies). Similarly, low-grade time-averaged proteinuria was associated with a higher risk of kidney outcomes (pooled hazard ratio, 2.87; 95% CI, 1.48 to 5.56; seven studies) and a significantly steeper annual decline in eGFR (mean difference, -1.02 ml/min per 1.73 m 2 per year; 95% CI, -1.60 to -0.45; four studies). Subgroup analyses and leave-one-out sensitivity analyses were consistent with the overall findings. CONCLUSIONS: Low-grade proteinuria, whether assessed at baseline or over time, is an important predictor of kidney disease progression in patients with IgA nephropathy. These results reinforce recent clinical guidelines recommending proteinuria control under 0.5 g/d. Long-term suppression of proteinuria should be considered a key therapeutic goal in IgA nephropathy.
引用
- Yamaguchi Y, Kosugi T, Sasaki T, et al. The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2025. PMID: 41385286. doi:10.2215/CJN.0000000952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。